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The Relationship Between Aldosterone and Left Ventricular Hypertrophy in Hypertensive Patients 
 
Abstract 
Background - Aldosterone is a pertinent hormone in naturally elevating blood pressure 
within the body by increasing fluid retention in the body via electrolyte reabsorption in the 
kidneys. Consequently, aldosterone can have an indirect effect on the incidence of LVH 
considering the hormone can reinforce high blood pressure. However, recent studies have 
suggested that aldosterone and the renin-angiotensin-aldosterone-system (RAAS) may have a 
direct role in leading to an increase in left ventricular mass. Patients with hyperaldosteronism, 
otherwise elevated circulating aldosterone, have shown high frequencies of LVH regardless of 
the presence of hypertension. Furthermore, cardiomyocytes have been seen to contain 
mineralocorticoid receptors that bind to aldosterone and can be affected by different RAAS 
inactivating medications. Overall, current research suggests there may be a regression between 
LVH and aldosterone.  
Methods and Results – A retrospective model comparing plasma aldosterone levels and 
left ventricular hypertrophy measurements in a hypertensive cohort of African Americans from 
the AdDReaCH trial. Follow-up over the course of a year allowed for multivariate analysis to 
determine whether elevated levels of plasma aldosterone induced changes in left ventricular mass 
and diastolic function independent of blood pressure and other variables. Left ventricular 
hypertrophy was assessed through various left ventricular measurements from contrast-aided 
MRI examinations. Though average LVMI was greater in patients with greater aldosterone-renin 
ratios, multivariate analysis suggested that plasma aldosterone-renin ratio does not have a 
significant, independent relationship to the incidence and severity of LVH. Results call for 
further research on the topic, as the current study confounds results from prior studies. 
Introduction 
Cardiovascular disease (CVD) is by far the leading cause of death within the United 
States. Specifically, congestive heart failure (CHF) continues to complicate the health of 
Americans annually. The pathophysiology underlying any form of CHF typically involves some 
cardiac remodeling. One of the most prominent physical changes in the heart involve the 
enlargement of the left ventricle, otherwise known as left ventricular hypertrophy (LVH). 
However, while some mechanisms of LVH is well studied, other mechanisms complicate our 
understanding of the condition. One such complication involves the Renin-Angiotensin-
Aldosterone System (RAAS). More specifically, there remains some uncertainty as to whether 
the different hormones of the RAAS have some sort of direct causational effect on LVH and 
diastolic function.    
Purpose 
Urban communities continue to face high incidences of hypertension and hence, are put 
in great risk of left ventricular hypertrophy. It is critical for the treatment of these patients to 
understand the various components of LVH causation and development. The renin-angiotensin-
aldosterone system continues to complicate our understanding of cardiac morphology, therefore 
calling for further research. The purpose of this investigation is to determine whether there are 
associations with serum aldosterone and left ventricular mass differences. Furthermore, the 
analysis shall study potential correlations of left ventricular mass with aldosterone and plasma 
aldosterone-renin ratio.  
Background 
The Renin-Angiotensin-Aldosterone System Regulates Blood Pressure  
To investigate what kind of role aldosterone has in the pathology of left ventricular 
hypertrophy, it is necessary to have a closer look at the functionality of RAAS and the 
mechanisms involved in the causation of LVH.  
The renin-angiotensin-aldosterone system is a natural hormonal pathway in the body that 
regulates ion levels and blood pressure. In response to reduced renal blood flow, the kidneys 
release renin, which allows for the conversion of inactive angiotensinogen to angiotensin I. 
Angiotensin converting enzymes (ACE) then act on angiotensin I and convert it to angiotensin II 
(AngII), which causes vasoconstriction, sympathetic activation, and increase blood flow. 
Angiotensin II also stimulates the release of aldosterone, a hormone which causes the kidneys to 
increase reabsorption of sodium and potassium, from the adrenal glands, which ultimately 
increases water volume and blood pressure. The RAAS is simplified in the diagram below 
(RAAS Schematic).  
 
 
Schematic 1. Renin-angiotensin-aldosterone system breakdown [1] 
 
The Renin-Angiotensin-Aldosterone System Indirectly Stimulates Heart Enlargement 
RAAS is one of the primary mechanisms in the body that regulates blood pressure. As 
such, the system, and especially aldosterone, has an indirect effect on cardiovascular health. An 
irregularly hyperactive RAAS can result in elevated blood pressure, which effectively increases 
the workload of the heart. Seeing that the heart is composed of myocytes, this increased 
workload can cause a thickening in the muscle fibers of the left ventricle, similar to muscle 
growth seen in skeletal muscle after exercise. This enlargement, known as left ventricular 
hypertrophy, involves fibrosis and stiffening of the heart, therefore inducing complications in 
ejection fraction and overall functionality.  
Interestingly, left ventricular hypertrophy is a useful morphology of the heart to an 
extent. The enlargement of the heart serves as a method to compensate for the hemodynamics 
introduced in hypertensive conditions [2]. However, while LVH helps the body to initially adapt 
to high blood pressure, further stimulation of the heart becomes maladaptive [3]. Continued 
growth of the left ventricle puts patients at risk of heart failure, heart attack, stroke, and, 
ultimately, death.  
Evidence for a Direct Relationship Between Renin-Angiotensin-Aldosterone System Hormones 
and Left Ventricular Hypertrophy 
The relationship between hypertension and LVH is well pronounced, justifying the 
indirect effect RAAS has on cardiac morphology. However, recent evidence is now suggesting 
the RAAS may also introduce direct effects on cardiomyocytes in the development of LVH.  
Cardiomyocytes contain AT1 and AT2 receptors, which principally attach to Angiotensin 
II (AngII) and conduct a response within the body [4]. Binding of AngII to AT1 receptors results 
in sodium conservation, aldosterone secretion, and vasoconstriction while binding to AT2 brings 
about vasodilation and decreased cell growth [4]. The two receptors effectively contrast each 
other in their effects on cardiac morphology.  
In the case of LVH, activation of AT1 receptors by AngII stimulate cardiac remodeling 
and hypertrophy. Recent studies have investigated the use of angiotensin converting enzyme 
inhibitors (ACEI) in preventing the increase in left ventricular mass by AngII. Typically, ACEIs 
are used to treat hypertension and can indirectly prevent LVH in the instance of a decrease in 
blood pressure. However, without an associated change in blood pressure, ACEIs tend to only 
halt fibrosis without a decrease in hypertrophy [4]. Part of the issue may arise from the lack of 
specificity of ACEIs, as blockage of angiotensin conversion inhibits both the hypertrophic 
effects of AT1 receptor stimulation and the antigrowth effects of AT2 receptor stimulation. 
Therefore, a more novel approach to understanding the direct effects of AngII on LVH would be 
to investigate the blockage of angiotensin receptors. In multiple studies, angiotensin receptor 
blockers (ARBs) that specifically inhibit AT1 receptors have shown a regression with LVH [3], 
[5]. Ultimately, AngII seems to play a direct role in the development of LVH. However, what 
may be of more interest is the impact AngII has on LVH through its ability to stimulate the 
release of aldosterone.  
Unclear Role of Aldosterone in Left Ventricular Hypertrophy 
Aldosterone is known to have a large indirect impact on left ventricular hypertrophy due 
to its ability to increase blood volume and pressure. However, there is evidence that suggests 
aldosterone may directly affect fibrosis and cardiac remodeling. Cardiomyocytes have been 
found to contain mineralocorticoid receptors (MRs), which primarily react with aldosterone [6]. 
An interesting angle to approach aldosterone’s effect on LVH is to look at animal and human 
models with hyperaldosteronism.  
 Hyperaldosteronism is a condition in which patients have abnormally high levels of free 
aldosterone. Some studies have shown that patients with early hyperaldosteronism tend to have a 
higher incidence and severity of LVH compared to patients with hypertension [7]. In fact, 
subjects have shown severe forms of LVH due to aldosteronism independent of any effect from 
blood pressure [8]. This suggests aldosterone may exert some change on cardiomyocyte activity 
outside of its typical effect on blood pressure. More specifically, studies have shown that MR 
expression in the heart typically results in some form of cardiotoxic effect [6].  
 Another approach to accurately determining aldosterone’s impact on the development of 
left ventricular hypertrophy would be to study the effect of mineralocorticoid receptor 
antagonists (MRAs) on left ventricle mass and function. Spironolactone is a common MRA that 
is largely used to treat heart failure with preserved ejection fraction [9]. The RALES trial proved 
on a large scale the positive effects of spironolactone in treating heart failure and exemplified the 
cardiac benefit from blocking aldosterone [6]. In the context of LVH, spironolactone has shown 
to significantly decrease left ventricular mass, though the drug did not exert any effects on actual 
diastolic function [9]. 
 Eplerenone is a selective aldosterone blocker that has shown to have beneficial cardiac 
effects similar to spironolactone. The EPHESUS trial suggested eplerenone significantly helped 
with post MI reparative healing and effectively reduced collagen-volume in the myocardium 
[10]. With blood pressure staying constant, aldosterone was shown once more to have some sort 
of morphological effect on the heart.  
 The mechanisms through which the heart is altered from MR activation involves changes 
in the extracellular matrix (ECM). Aldosterone has been linked to T-channel activity and 
increases the relative concentration of collagen within the ECM, therefore increasing mass and 
stiffening the muscles of the heart [8], [11].  
 Despite the clinical trials discussed that predict a regression between aldosterone and left 
ventricular mass, other studies have suggested complicated results. A study investigating the 
effect of aldosterone associated with salt intake on LVH showed that baseline aldosterone is not 
independently related to LV mass while post-saline dose aldosterone is independently related to 
LV mass [12], [13]. Such a result may suggest that salt is required to activate MR expression in 
cardiomyocytes via oxidative stress of intracellular redox states [12].  
 
 
Mechanisms Outside of the Renin-Angiotensin-Aldosterone System that Affect Left Ventricular 
Hypertrophy 
 In order to compare plasma aldosterone levels to left ventricular hypertrophy, it is 
necessary to consider and compensate for other factors that may result in heart enlargement. 
Patients with chronic kidney disease (CKD) have been shown to have incidences and severities 
of LVH even greater than those in hypertensive patients [14]. A proposed mechanism of LVH 
related to CKD involves fibroblast growth factor-23 (FGF23). FGF23 is an endocrine hormone 
that regulates phosphorus homeostasis [14]. As such, FGF23 expression increases as the kidney’s 
ability for phosphorus excretion decreases in CKD patients. Interestingly, FGF23 can alter gene 
expression in cardiomyocytes and cardiac fibroblasts as well, particularly leading to ECM 
deposition, hypertrophy, and apoptosis of myocytes [14]. FGF23 has also been seen to be 
associated with elevated levels of cardiac troponins, suggesting a relationship between FGF23 
and cardiac distress [15].  
 Chronic kidney disease has been shown to have a significant relationship with 
cardiovascular health and therefore has to be accounted for in any study of LVH.  
Accurate Measurement of Left Ventricular Mass and Diastolic Function 
 One of the challenges in studying left ventricular mass and heart function lies in 
accurately measuring different pertinent variables. Current recommendations in measuring LVH 
suggest the use of echocardiography in quantifying the following variables: morphologic change, 
mitral inflow, pulmonary venous flow, flow propagation velocity, diastolic velocity, left 
ventricular untwisting, and left ventricular filling pressures [16]. Prior studies involving the study 
of aldosterone and left ventricular hypertrophy have taken the recommended approach and 
utilized echocardiography to quantify the incidence and severity of LVH. However, it is arguable 
that magnetic resonance imaging (MRI) may be able to provide a more accurate representation of 
LVH and diastolic function in most patients. Few studies on aldosterone-LVH regression have 
been conducted with an MRI as the primary instrument for left ventricular mass and diastolic 
function measure. Utilization of MRI may therefore provide more accurate, interesting, and 
potentially different results   
Racial Disparities Underlying Hypertension and Left Ventricular Hypertrophy 
 Race has been proven to be a significant determinant of hypertension incidence in any 
population. Typically, African Americans have a higher risk of having high blood pressure and, 
therefore, early onset heart disease, as seen by the bar graph below [17]. 
Bar Graph 1. Racial Distribution of Cardiovascular Disease [18]. 
 
African Americans exemplify similar risk in developing left ventricular hypertrophy and 
diastolic dysfunction based on modifiable sociodemographic variables [19]. For these reasons, 
African Americans provide a cohort of individuals that can be used to investigate LVH in 
patients with essential hypertension.  
Hypothesis 
 It is hard to ignore the evidence connecting aldosterone to the development of left 
ventricular hypertrophy. Current understanding of the mechanisms involving RAAS and the 
heart suggest there would be a positive relationship between serum aldosterone levels and left 
ventricular mass. We hypothesize such a trend will be significant amongst multiple variables 
measuring left ventricular remodeling.  
Methods 
Study Design 
The current study took a prospective approach with a priori anticipation for controlling 
for aldosterone-renin ratio and aldosterone in assessing the relationship between plasma 
aldosterone levels and left ventricular hypertrophy. All patient data was pooled from the 
AdDReaCH trial (NCT01260476), a prospective, longitudinal, randomized, controlled, IRB 
reviewed study. Data points related to blood pressure, left ventricular hypertrophy, plasma 
aldosterone, and other useful values were collected by standard protocol of the AdDReaCH trial 
and were utilized retrospectively.  
Study Population 
 The AdDReaCH study selectively enrolled asymptomatic, hypertensive, African 
American patients from an urban, academic medical center. The study assessed the efficacy of 
Vitamin D supplementation, in conjunction with antihypertensive therapy, in reducing the 
severity of left ventricular hypertrophy. Recruited had blood pressures that measured greater than 
160/90 and were vitamin D deficient. Any patients with a hypertensive emergency or had any 
clinical history of extraneous cardiovascular, renal, hepatic, or neurological conditions were 
excluded. 
Study Protocol 
 Subjects who were enrolled into the AdDReaCH study were screened within the 
emergency department (ED). Patients then proceeded for follow-up as outpatients for cardiac 
MRI examinations and blood pressure intervention in order to assess the effects of Vitamin D 
therapy on left ventricular hypertrophy and blood pressure. Cardiac magnetic resonance (CMR) 
imaging took place a week prior to randomization for screening purposes as well as 16 and 52 
weeks after randomization for follow-up. Blood pressure was measured in the ED, two weeks 
prior to randomization, as well as at all follow-up CMR visits.  Plasma aldosterone and renin was 
measured at screening and 52 week CMR appointments. Patients received antihypertensive 
medications over the course of the year along with either placebo or vitamin D supplement.  
 Blood pressure readings throughout the study were collected from automated brachial 
cuffs and typically recorded as an average of two readings done immediately after one another. 
Left ventricular hypertrophy and diastolic function variables were measured through the 
performance of gadolinium contrast-guided MRI. Such variables included left ventricular mass 
(LVM), left ventricular mass indexed (LVMI) to body surface area (BSA), septal wall thickness, 
anterior wall thickness, and left ventricular stroke volume (LVSV).  
 Original data was retrieved from Oncore (Forte Research Systems, Madison, WI) and 
was extracted into Microsoft Excel.  
Data Analysis 
 Seeing that renin causes indirect change in aldosterone release, it is necessary to 
compensate for its impact to better organize patients in the current study with regards to the 
magnitude of serum aldosterone levels prior to RAS activation. Subject data was organized into 
four distinct groups defined by varying renin and aldosterone levels.  
Table 1. Criteria for Different Renin-Aldosterone Analysis Groups 
Plasma Renin-Aldosterone 
Group 
Plasma Renin Level 
(ng/mL/hr) 
Plasma Aldosterone Level 
(ng/dL) 
Low Renin 
Low Aldosterone < 1 < 15 
Low Renin 
High Aldosterone < 1 > 15 
High Renin 
Low Aldosterone > 1 < 15 
High Renin 
High Aldosterone > 1 > 15 
 
The four groups were assessed for a difference in left ventricular mass at baseline and 
follow-up using mean and median.  
Plasma Aldosterone-renin ratios (ARR) are typically used to diagnose primary 
aldosteronism and provide another measure of renin-compensated plasma aldosterone in the 
body. The typical cutoff to distinguish aldosteronism from healthy patients is 30 ng/dL per 
ng/(mL x h). As such, subjects were divided into two groups; one above and one below the ARR 
cutoff. Student’s t-test and chi-square tests were done to compare LVM measurements in patients 
with high and low calculated-ARRs. Similar analysis was completed to compare patients with 
serum aldosterone measurements above and below the healthy upper limit (15 ng/dL).  
Multivariate least-squares regression modeling was completed to determine if plasma 
aldosterone, plasma renin, and plasma aldosterone-renin ratio had an independent correlation 
with LVM regression whilst controlling for age, sex, blood pressure, creatinine, and sodium at 
the screening and 52-week CMR. Least-squares regression modeling was also completed to 
determine if a change in plasma aldosterone and plasma aldosterone-renin ratio from screening 
to 52-week follow up resulted in a change in LVM. 
Results 
 Data was abstracted from 113 subjects, of which 101 subjects had relevant aldosterone 
and LVMI measurements completed up until the 52 week follow up. All subjects were African 
American, with 53% of patients being female. It is important to note that all subjects had some 
form of left ventricular hypertrophy, otherwise they were excluded from the study. As such, the 
data gives insight not to the presence of hypertrophy in relation to aldosterone, but rather the 
changes in hypertrophy severity.  
  
Table 2. Distribution of Renin-Aldosterone Analysis Groups 
Group N Mean LVMI Median LVMI Low Aldosterone, Low Renin 62 96.8056 96.5 Low Aldosterone, High Renin 41 97.3934 93.17 High Aldosterone, Low Renin 6 108.74 97.66 High Aldosterone, High Renin 4 92.1625 85.82  
 In the analysis of subjects based on aldosterone-renin ratio threshold, only 14 subjects 
presented with a ratio greater than 30 ng/dL.  
Histogram 1. Distribution of Patients with Regards to Aldosterone-Renin Ratio 
 
ARR 
 Patients below and above the threshold were compared for a significant difference in 
LVMI. Not assuming equal variances, a t-test for equality of means suggested no significant 
difference in LVMI (t = 1.458). T-test comparing patients above and below the aldosterone 
threshold of 15 ng/dL provided a similar, insignificant difference between groups (t = -0.641).  
 On multiple regression modeling, aldosterone-renin ratio was statistically insignificant 
predictor of LVMI while controlling for age, sex, and systolic blood pressure. The least squared 
regression for ARR resulted in an R2 = 0.213, suggesting a far from linear relationship to LVMI. 
Analysis of individual coefficients suggested only the female gender and systolic blood pressure 
are significant predictors in the development of LVH.  
Table 3. Multivariate Regression Significance Results  
Coefficientsa 
Model 
Unstandardized Coefficients Standardized Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) 71.887 14.383  4.998 .000 
ARR .044 .071 .058 .615 .540 
Age .122 .162 .068 .755 .452 
Female -12.631 2.873 -.392 -4.396 .000 
SBP .151 .058 .243 2.598 .011 
a. Dependent Variable: LVMI 
 
  
Graph 1. Multivariate Regression Model of LVMI VS ARR 
 
 The final analysis involved an independent regression of change in LVMI versus change 
in aldosterone-renin ratio. Change in aldosterone-renin ratio was a poor indicator of change in 
LVMI (p = 0.12, R2 = 0.0373).  
  
ARR 
LVM
I 
Graph 2. Regression of Change in LVMI VS Change in ARR 
 
Discussion 
 Average left ventricular mass was the greatest in patients with a low renin but high 
aldosterone levels, coinciding with our stated hypothesis that patients with greater free 
aldosterone will have consequently greater LVMIs. However, upon closer analysis of 
aldosterone-renin ratios, we saw there were not significantly different LVMIs in patients with 
greater ARRs. As such, the hypothesis regarding a positive relationship between serum 
aldosterone and left ventricular remodeling could not be validated.  
 Current science has been suggesting that serum aldosterone has some effect on left 
ventricular mass. However, physicians have had a hard time getting conclusive and repetitive 
results. The EPHESUS and RALES trials provided a strong basis to support the novel approach 
of utilizing aldosterone receptor blockers to treat heart failure and MI [10, 20]. Studies regressing 
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LVH with primary aldosteronism have also suggested some connection between cardiac 
remodeling and serum aldosterone levels [6]. However, studies with similar research models to 
the current investigation have suggested that aldosterone does in fact have an insignificant 
relationship to cardiac structure [21]. Other studies imply a more complex system linking 
aldosterone and LVM. A recent investigation found that post-saline load aldosterone levels, as 
opposed to baseline aldosterone levels, are good predictors of LVM, implying some role of 
sodium in aldosterone-mediated cardiac remodeling [12]. Overall, the literature is inconclusive 
and calls for more research to be done on the topic.  
Limitations 
 The current study is a retrospective study and was therefore limited in the number and 
types of patients that were investigated. Few subjects were found to have elevated aldosterone 
levels or aldosterone-renin ratios, therefore greatly limiting the breadth of the sample. This 
limitation could be accounted for through a research model in which there was active enrollment 
of patients with elevated serum aldosterone, rather than leaving it up to retrospective chance.  
 All patients enrolled were required to have some form of left ventricular hypertrophy. As 
such, the investigation was limited to studying the relationship between aldosterone and LVH 
severity, as opposed to LVH incidence.  
 The sample size was limited by the small portion of subjects that actually completed up 
until the 52 week follow up. A large portion of the data had to be neglected due to incomplete 
data sets involving LVMI and aldosterone. The gaps in data also restricted the different variables 
controlled for in the multivariate regression.  
 
Conclusion 
 In this investigation, we could not find a significant and independent relationship 
between serum aldosterone and left ventricular mass. Based on our data, there cannot be any 
conclusions made as to whether aldosterone-related therapy would be effective in treating 
patients with left ventricular hypertrophy. Further study is necessary to investigate other 
significant factors that may play a role in left ventricular remodeling in conjunction with elevated 
serum aldosterone levels, such as kidney function and sodium loading. The current study 
provides another building block in determining the direct effect of aldosterone on the heart.  
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